REPLIGEN CORP — Director's Dealing 2023

Feb 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2023-02-06

Reporting Person: Madaus Martin D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-06	Common Stock	A	111	$0.00	Acquired	111	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-06	Stock Option (Right to Buy)	$192.02	A	239	Acquired	2033-02-06	Common Stock (239)	Direct
2023-02-06	Stock Option (Right to Buy)	$192.02	A	1819	Acquired	2033-02-06	Common Stock (1819)	Direct

Footnotes

F1: Mr. Madaus was awarded 111 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 18, 2023, the date of the annual meeting of the Company's shareholders. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: Award vests in full on May 18, 2023, the date of the annual meeting of the Company's shareholders.

F3: The shares vest in equal annual instalments over a three-year period with each such vesting date occurring on the earlier of the anniversary of the grant date or the date of the annual meeting of the Company's shareholders of the applicable year of such three-year period.